These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25738310)

  • 1. Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2.
    Wang Z; Zhao Z; Wu T; Song L; Zhang Y
    Neoplasma; 2015; 62(2):172-9. PubMed ID: 25738310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo.
    Li XZ; Sun YL; Cao LQ; Li MJ
    Neoplasma; 2016; 63(6):880-887. PubMed ID: 27565326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
    He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
    Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
    Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
    Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
    Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells.
    Şirin N; Elmas L; Seçme M; Dodurga Y
    Gene; 2020 May; 737():144428. PubMed ID: 32045658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.
    Omar HA; Tolba MF; Hung JH; Al-Tel TH
    Front Pharmacol; 2016; 7():463. PubMed ID: 27965580
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and αVβ3 Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells.
    Li J; Zhou P; Li L; Zhang Y; Shao Y; Tang L; Tian S
    PLoS One; 2016; 11(7):e0158592. PubMed ID: 27391603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
    Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
    Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
    Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
    Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
    BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
    Lim SC; Choi JE; Kang HS; Han SI
    Int J Cancer; 2010 Apr; 126(7):1582-95. PubMed ID: 19728331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.